Minimally invasive parenchyma-sparing pancreatectomy (mi-psp) decreases the risk of postoperative diabetes and exocrine insufficiency for benign pancreatic tumors.

• Only 9.8% of mi-psp patients developed new or worsening diabetes compared to 23% after standard minimally invasive pancreatectomy (mi-p).
• The 5-year cumulative incidence of new-onset diabetes was 26.7% for mi-psp vs. 38.9% for mi-p (p=0.008).
• Pancreatic exocrine insufficiency occurred in 5.4% of mi-psp patients vs. 22% of mi-p patients (p=0.001).

Consider mi-psp to minimize post-surgical metabolic complications in suitable patients.